Deutsche Bank Aktiengesellschaft Reiterates Sell Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reiterated by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday,London Stock Exchange reports. They currently have a £115 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential downside of 4.45% from the stock’s previous close.

A number of other research firms have also recently issued reports on AZN. Jefferies Financial Group reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research note on Monday. Berenberg Bank restated a “buy” rating and set a £160 price target on shares of AstraZeneca in a report on Tuesday, July 28th. Finally, Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of £152.17.

AstraZeneca Stock Up 2.5%

LON:AZN traded up GBX 296 during midday trading on Wednesday, reaching £120.36. 1,763,656,500 shares of the stock traded hands, compared to its average volume of 40,949,230. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market capitalization of £186.66 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The business has a 50-day moving average of £133.11 and a two-hundred day moving average of £139.88. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.